Sparrow is developing next-generation steroids: combinations of a steroid (e.g., prednisolone) with a HSD-1 inhibitor (e.g., SPI-62). Those products are expected to have the same efficacy as today's steroids, but with much lower side effect burden. They could be the first medicines for many patients with autoimmune diseases that provide strong efficacy, safety, convenience, and cost-effectiveness. During the BIO CEO Investor conference, CEO David Katz discussed next-generation steroids with Proactive Investors' Christine Corrado.

copyright (c) 2020 Sparrow Pharmaceuticals, Inc.